至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Mucosal IgA response elicited by intranasal immunization of Lactobacillus plantarum expressing surface-displayed RBD protein of SARS-CoV-2

Int J Biol Macromol. 2021-09; 
Letian Li, Maopeng Wang, Jiayi Hao, Jicheng Han, Tingting Fu, Jieying Bai, Mingyao Tian, Ningyi Jin, Guangze Zhu, Chang Li
Products/Services Used Details Operation
Monoclonal Antibody Services When the OD600 of the broth reaches 0.3–0.5, the inducer SppIP [18] (GenScript Biotech, China) was added into the culture at a concentration of 50 ng/mL...The membrane was blocked by 5% skim milk solution at room temperature for 2 h, followed by incubating with anti-HA tag rabbit polyclonal antibody (1:1000, Proteintech, USA) or anti-RBD mouse monoclonal antibody 13E10D5 (1:1000, GenScript Biotech, China) at 4 °C overnight and washed with TBST four times...The RBD protein expressed by the Chinese hamster ovary (CHO) cell (GenScript Biotech, China) was utilized as standard at 31.25 ng, 62.5 ng, 125 ng, 250 ng, and 500 ng amounts Get A Quote

摘要

Coronavirus Disease 2019 (COVID-19) caused by a novel betacoronavirus SARS-CoV-2 has been an ongoing global pandemic. Several vaccines have been developed to control the COVID-19, but the potential effectiveness of the mucosal vaccine remains to be documented. In this study, we constructed a recombinant L. plantarum LP18:RBD expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein via the surface anchoring route. The amount of the RBD protein was maximally expressed under the culture condition with 200 ng/mL of inducer at 33 °C for 6 h. Further, we evaluated the immune response in mice via the intranasal administration of LP18:RBD. The results showed that the LP18:RBD significantly elici... More

关键词

Intranasal immunization, Lactobacillus plantarum, Mucosal vaccine, Receptor-binding domain (RBD), SARS-CoV-2